1. Home
  2. SEER vs CGTX Comparison

SEER vs CGTX Comparison

Compare SEER & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seer Inc.

SEER

Seer Inc.

HOLD

Current Price

$1.70

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.87

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEER
CGTX
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
94.5M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
SEER
CGTX
Price
$1.70
$0.87
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
203.2K
1.4M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
9.40
62.79
EPS
N/A
N/A
Revenue
$16,578,000.00
N/A
Revenue This Year
$2.14
N/A
Revenue Next Year
$25.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$1.65
$0.22
52 Week High
$2.41
$3.83

Technical Indicators

Market Signals
Indicator
SEER
CGTX
Relative Strength Index (RSI) 41.54 44.37
Support Level $1.69 $0.55
Resistance Level $1.97 $1.19
Average True Range (ATR) 0.04 0.13
MACD 0.00 -0.01
Stochastic Oscillator 33.33 50.56

Price Performance

Historical Comparison
SEER
CGTX

About SEER Seer Inc.

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: